SCHEMBL14161069

SCHEMBL14161069

CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)OCC(=O)C(C)(C)C)C(C)(C)CCC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.67
MAPT P10636 7/20 0.67
CYP3A4 P08684 6/20 0.67
RXRA P19793 5/20 0.67
RARA P10276 4/20 0.67
RARB P10826 4/20 0.67
RARG P13631 4/20 0.67
PTGS1 P23219 4/20 0.67
APP P05067 4/20 0.67
SNCA P37840 4/20 0.67
MAPK1 P28482 3/20 0.67
ALOX15 P16050 3/20 0.67
RXRB P28702 2/20 0.67
RXRG P48443 2/20 0.67
RORC P51449 2/20 0.67
ADORA3 P0DMS8 2/20 0.67
HTR2B P41595 2/20 0.67
BLM P54132 2/20 0.67
HIF1A Q16665 2/20 0.67
HSD17B10 Q99714 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14300778 1.00 ALDH1A1 (0.67) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL21427636 1.00 ALDH1A1 (0.67) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL13124361 1.00 ALDH1A1 (0.67) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL14164136 1.00 ALDH1A1 (0.67) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL4898397 0.90 ALDH1A1 (0.72) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL4784917 0.90 ALDH1A1 (0.72) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL8648149 0.90 ALDH1A1 (0.72) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL8631847 0.90 ALDH1A1 (0.72) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL4892803 0.90 ALDH1A1 (0.72) ALDH1A1MAPTCYP3A4RXRARARA
SCHEMBL342404 0.90 ALDH1A1 (0.72) ALDH1A1MAPTCYP3A4RXRARARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11801210-B2 Retinol replacement in skin treatment SYMRISE AG (DE) 2023-10-31 US disclosed
US-11801210-B2 Retinol replacement in skin treatment SYMRISE AG (DE) 2023-10-31 US disclosed
US-20210045983-A1 RETINOL REPLACEMENT IN SKIN TREATMENT SYMRISE AG (DE) 2021-02-18 US disclosed
US-20150005266-A1 TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS MOLECULAR DESIGN INTERNATIONAL, INC. 2015-01-01 US disclosed
US-20150005266-A1 TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS MOLECULAR DESIGN INTERNATIONAL, INC. 2015-01-01 US disclosed
US-8912175-B1 Topical compositions for treatment of skin conditions MOLECULAR DESIGN INTERNATIONAL, INC. (US) 2014-12-16 US disclosed
US-8912175-B1 Topical compositions for treatment of skin conditions MOLECULAR DESIGN INTERNATIONAL, INC. (US) 2014-12-16 US disclosed
US-8865694-B2 Topical compositions for treatment of skin conditions MOLECULAR DESIGN INTERNATIONAL, INC. (US) 2014-10-21 US disclosed
US-8865694-B2 Topical compositions for treatment of skin conditions MOLECULAR DESIGN INTERNATIONAL, INC. (US) 2014-10-21 US disclosed
US-20140066414-A2 TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS MOLECULAR DESIGN INTERNATIONAL, INC. 2014-03-06 US disclosed
US-20140066414-A2 TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS MOLECULAR DESIGN INTERNATIONAL, INC. 2014-03-06 US disclosed
US-20130237505-A1 TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS CONCERT, LLC (US) 2013-09-12 US disclosed
US-20130237505-A1 TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS CONCERT, LLC (US) 2013-09-12 US disclosed
WO-2008070116-A2 TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS CONCERT, LLC (US) 2008-06-12 WO disclosed
US-20080139518-A1 Synergistic effect attributable to combination of a retinoid component and a salicylic acid component; combination of the two active ingredients provided a greater overall anti-acne effect than a treatment comprising benzoyl peroxide CONCERT, LLC 2008-06-12 US disclosed
US-20080139518-A1 Synergistic effect attributable to combination of a retinoid component and a salicylic acid component; combination of the two active ingredients provided a greater overall anti-acne effect than a treatment comprising benzoyl peroxide CONCERT, LLC 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005266-A1 TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS RARA, RARB, CUTA ALDH1A1 281/4885MAPT 3408/4885CYP3A4 4320/4885
US-20210045983-A1 RETINOL REPLACEMENT IN SKIN TREATMENT RBP1, RBP4, LRAT ALDH1A1 23/4885MAPT 4310/4885CYP3A4 2306/4885
US-11801210-B2 Retinol replacement in skin treatment RBP1, RBP4, LRAT ALDH1A1 22/4885MAPT 4158/4885CYP3A4 2101/4885
US-20130237505-A1 TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS RARA, RARB, CUTA ALDH1A1 281/4885MAPT 3408/4885CYP3A4 4320/4885
US-20140066414-A2 TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS RARA, RARB, CUTA ALDH1A1 281/4885MAPT 3408/4885CYP3A4 4320/4885
US-20080139518-A1 Synergistic effect attributable to combination of a retinoid component and a salicylic acid component; combination of the two active ingredients provided a greater overall anti-acne effect than a treatment comprising benzoyl peroxide RARA, RARB, CHUK ALDH1A1 165/4885MAPT 4791/4885CYP3A4 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.